These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19064977)

  • 1. Monitoring for lack of benefit: a critical component of a randomized clinical trial.
    Freidlin B; Korn EL
    J Clin Oncol; 2009 Feb; 27(4):629-33. PubMed ID: 19064977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comment on futility monitoring.
    Freidlin B; Korn EL
    Control Clin Trials; 2002 Aug; 23(4):355-66. PubMed ID: 12161079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A general inefficacy interim monitoring rule for randomized clinical trials.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2010 Jun; 7(3):197-208. PubMed ID: 20423925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
    Ball G; Piller LB; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S2-4. PubMed ID: 21664987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trials of home uterine activity monitoring: a review and critique.
    Grimes DA; Schulz KF
    Obstet Gynecol; 1992 Jan; 79(1):137-42. PubMed ID: 1727572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials and the COVID-19 pandemic.
    Retsas S
    Hell J Nucl Med; 2020; 23(1):4-5. PubMed ID: 32361715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised placebo-controlled trials of surgery: ethical analysis and guidelines.
    Savulescu J; Wartolowska K; Carr A
    J Med Ethics; 2016 Dec; 42(12):776-783. PubMed ID: 27777269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of treatment trials for functional gastrointestinal disorders.
    Veldhuyzen van Zanten SJ; Talley NJ; Bytzer P; Klein KB; Whorwell PJ; Zinsmeister AR
    Gut; 1999 Sep; 45 Suppl 2(Suppl 2):II69-77. PubMed ID: 10457048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
    Borow KM; Yaroshinsky A; Greenberg B; Perin EC
    Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials.
    Djulbegovic B; Cantor A; Clarke M
    Account Res; 2003; 10(4):301-15. PubMed ID: 14989285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific barriers to the conduct of randomized trials.
    Duley L; Antman K; Arena J; Avezum A; Blumenthal M; Bosch J; Chrolavicius S; Li T; Ounpuu S; Perez AC; Sleight P; Svard R; Temple R; Tsouderous Y; Yunis C; Yusuf S
    Clin Trials; 2008; 5(1):40-8. PubMed ID: 18283079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.
    Dignam JJ; Bryant J; Wieand HS; Fisher B; Wolmark N
    Control Clin Trials; 1998 Dec; 19(6):575-88. PubMed ID: 9875837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are distinctive ethical principles required for cluster randomized controlled trials?
    Hutton JL
    Stat Med; 2001 Feb; 20(3):473-88. PubMed ID: 11180314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.